Global Myasthenia Gravis Drugs Market 2017-2021

Global myasthenia gravis drugs market forecast

Extensive research carried out by the market research analysts at Technavio has shown that the global myasthenia gravis drugs market will witness impressive growth and post a staggering CAGR of more than 13% over the forecast period. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects.

Global myasthenia gravis drugs market drivers

Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. For instance, Soliris (eculizumab) is one such drug that is currently in Phase III development stage. The drug acts by restricting the disease cells from affecting the immune system. Soliris (eculizumab) is anticipated to receive approval by the end of 2017 or in early 2018 in the US. Some of the other monoclonal antibodies in the pipeline include Novartis' CFZ-533 and GlaxoSmithKline's Benlysta. With several monoclonal antibody-based drugs in the pipeline, the market for myasthenia gravis drugs will have a positive outlook in the coming years.

Global myasthenia gravis drugs market trends